References
  1. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43(Suppl 1): S9-15, 2003
  2. Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 120(16):1864-74, 2007
  3. Thambar S, Kulkarni S, Amstrong S, Nikolarakos D. Botulinum toxin in the management of temporomandibular disorder: a systematic review. Br J Oral Maxillofac Surg. Mar 03, 2020 [Epub ahead of print]
  4. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMDpain: a randomized, controlled, double-blind multicenter study. Pain 152(9):1988-96, 2011
  5. Suvinen TI, Malmberg J, Forster C, Kemppainen P. Postural and dynamic masseter and anterior temporalis muscle EMG repeatability in serial assessment. J Oral Rehabil. 36(11):814-20, 2009
  6. Ohrbach R, editor. Diagnostic Criteria for Temporomandibular Disorders: Assessment Instruments. Version 15May2016.[Diagnostiset Kriteerit Purentaelimistön Kivuille ja Toimintahäiriöille (DC/TMD-FIN): Tutkimusinstrumentit: Finnish Version 25May2016] Sipilä K, Suvinen T, Trans.www.rdc-tmdinternational.org (Accessed on July 1, 2020).
  7. Suvinen T, Rantala M, Ahlberg J, Könönen M. RDCTMD_FIN. www.rdc-tmdinternational.org (Accessed on July 1, 2020).
  8. Pihut M, Wisniewska G, Majewski P, Gronkiewicz K, S Majewski. Measurement of occlusal forces in the therapy of functional disorders with the use of botulinum toxin type A. J Physiol Pharmacol 60(Suppl 8): 113-6, 2009
  9. Lee HJ, Kim SJ, Lee KJ, Yu HS, Baik HS. Repeated injections of botulinum toxin into the masseter muscle induce bony changes in human adults: A longitudinal study. Korean J Orthod. 2017;47(4):222-228